The landscape of cancer treatment is continually evolving, with a strong focus on enhancing the efficacy of existing therapies. Dihydromyricetin (DHM), a natural flavonoid, has demonstrated a remarkable ability to synergize with conventional chemotherapy drugs, offering a promising avenue for improving patient outcomes. NINGBO INNO PHARMCHEM CO.,LTD. explores this synergistic potential.

Chemotherapy resistance is a significant challenge, often leading to treatment failure. DHM addresses this by acting as a chemosensitizer. Its mechanisms include the downregulation of key survival proteins, such as Survivin, which normally protect cancer cells from death. By reducing Survivin levels, DHM makes cancer cells more susceptible to the cytotoxic effects of chemotherapy agents like paclitaxel and doxorubicin.

Studies have shown that when DHM is combined with these chemotherapy drugs, the therapeutic effect is significantly amplified. This means lower doses of chemotherapy might be effective, potentially reducing side effects, or that previously resistant tumors can become responsive again. This synergistic action is crucial for overcoming treatment plateaus and improving remission rates.

Furthermore, DHM's ability to modulate cellular pathways and its antioxidant properties may also contribute to its role in enhancing overall treatment effectiveness. The combination of DHM with chemotherapy represents a powerful strategy for more effective cancer management. NINGBO INNO PHARMCHEM CO.,LTD. provides access to high-quality DHM for researchers investigating these vital combination therapies.